Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.
James NE, Woodman M, De La Cruz P, Eurich K, Ozsoy MA, Schorl C, Hanley LC, Ribeiro JR. James NE, et al. Among authors: ozsoy ma. Front Immunol. 2022 Sep 5;13:965331. doi: 10.3389/fimmu.2022.965331. eCollection 2022. Front Immunol. 2022. PMID: 36131935 Free PMC article.
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity.
Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche RP, Qu R, Rosenberg L, Hamard PJ, Bykov Y, Green H, Gusain L, Chiappinelli KB, Ozsoy MA, Chui MH, Basili T, Gardner R, Walderich S, DeStanchina E, Greenbaum B, Gönen M, Vabret N, Weigelt B, Zamarin D. Brodeur MN, et al. Among authors: ozsoy ma. Sci Adv. 2024 Dec 6;10(49):eadk4851. doi: 10.1126/sciadv.adk4851. Epub 2024 Dec 4. Sci Adv. 2024. PMID: 39630912 Free PMC article.
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr, Mueller JJ, Makker V, Tew WP, O'Cearbhaill RE, Liu YL, Rubinstein MM, Troso-Sandoval T, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, Zamarin D. Friedman CF, et al. Among authors: ozsoy ma. Nat Med. 2024 May;30(5):1330-1338. doi: 10.1038/s41591-024-02942-7. Epub 2024 Apr 23. Nat Med. 2024. PMID: 38653864 Free PMC article. Clinical Trial.
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity.
Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche R, Qu R, Hamard PJ, Bykov Y, Green H, Chiappinelli KB, Ozsoy MA, Basili T, Gardner R, Walderich S, DeStanchina E, Greenbaum B, Gönen M, Weigelt B, Zamarin D. Brodeur MN, et al. Among authors: ozsoy ma. bioRxiv [Preprint]. 2023 Aug 11:2023.08.08.552544. doi: 10.1101/2023.08.08.552544. bioRxiv. 2023. Update in: Sci Adv. 2024 Dec 6;10(49):eadk4851. doi: 10.1126/sciadv.adk4851 PMID: 37609261 Free PMC article. Updated. Preprint.